Invst LLC Makes New $74,000 Investment in Cardiff Oncology, Inc. (NASDAQ:CRDF)

Invst LLC bought a new stake in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 36,000 shares of the company’s stock, valued at approximately $74,000.

Other large investors have also recently made changes to their positions in the company. Assenagon Asset Management S.A. increased its position in shares of Cardiff Oncology by 380.6% in the second quarter. Assenagon Asset Management S.A. now owns 1,215,922 shares of the company’s stock valued at $2,699,000 after buying an additional 962,940 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in Cardiff Oncology in the 2nd quarter valued at $256,000. XTX Topco Ltd acquired a new stake in Cardiff Oncology in the 2nd quarter valued at $185,000. Renaissance Technologies LLC increased its holdings in Cardiff Oncology by 82.9% in the 2nd quarter. Renaissance Technologies LLC now owns 157,490 shares of the company’s stock worth $350,000 after acquiring an additional 71,390 shares in the last quarter. Finally, Blair William & Co. IL raised its position in Cardiff Oncology by 32.2% during the second quarter. Blair William & Co. IL now owns 227,630 shares of the company’s stock worth $505,000 after acquiring an additional 55,450 shares during the period. 16.29% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Craig Hallum started coverage on shares of Cardiff Oncology in a research note on Friday, September 6th. They set a “buy” rating and a $8.00 target price for the company.

Cardiff Oncology Stock Down 7.5 %

Shares of CRDF opened at $2.47 on Wednesday. The firm’s fifty day moving average is $2.37 and its two-hundred day moving average is $3.21. The stock has a market cap of $114.98 million, a PE ratio of -2.74 and a beta of 1.95. Cardiff Oncology, Inc. has a 52-week low of $0.94 and a 52-week high of $6.42.

Cardiff Oncology (NASDAQ:CRDF) last released its earnings results on Thursday, August 8th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.01). Cardiff Oncology had a negative return on equity of 62.65% and a negative net margin of 6,143.91%. The business had revenue of $0.16 million during the quarter, compared to analysts’ expectations of $0.12 million. During the same period last year, the business earned ($0.25) earnings per share. As a group, research analysts anticipate that Cardiff Oncology, Inc. will post -1 earnings per share for the current year.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.